SPL (ASX:SPL) Announces Preliminary Financial Report
SPL (ASX:SPL) reports a 41% decrease in revenue and a 22% increase in loss for the year ended 30 June 2025.
Starpharma
SPL (ASX:SPL) reports a 41% decrease in revenue and a 22% increase in loss for the year ended 30 June 2025.
Starpharma (ASX:SPL) reports a 183% revenue increase and reduced losses in its FY25 financial results.
Starpharma (ASX:SPL) announces Q3 FY25 report with advancements in partnerships, product launches, and financial performance.